IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds
Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting
Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint
Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors
Study Validates “PEM” Scans As Biopsy Guidance Method
Prostatectomy Lowers Death Risk Compared to Watchful Waiting
Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk
Acupuncture Can Relieve Side Effects of Hormone Treatment
Selumetinib Displays Positive Results, 60% with Stable Disease
National Health Organizations Warn of Risks in Indoor Tanning
Clinical Trials Approved By NCI CTEP Last Month
SWOG Launching New Study Based on Recurrence Test Scores
Centocor Withdraws Yondelis After FDA Calls for New Study
FDA Approves New Device For Glioblastoma Multiforme
EU Gives Marketing Approval For HBV Sequencing Test
Roche Markets CMV Test in Europe
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
